Can B

Can B, now rebranded at the public holding company level as Nascent Pharma Holdings, is a U.S. OTC-listed cannabis-focused healthcare company centered on the protection, licensing, and commercialization of cannabinoid patent assets. The company historically developed and sold hemp- and CBD-based consumer wellness products under brands such as Canbiola, but since 2024 it has shifted its primary strategic focus toward pharmaceutical intellectual property. Its core assets are two issued U.S. patents covering cannabis extracts, methods of preparation, and cannabinoid formulations, including a pain-management patent. The company appears to be operating more as an IP commercialization and licensing vehicle than as a traditional clinical-stage drug developer. It remains active as a public company and trades on the OTC market under the symbol NASC following its September 16, 2025 name and ticker change from Can B Corp. and CANB.